Francis Worden, MD
Enriched profileNancy Wigginton Oncology Research Professor of Thyroid Cancer; Clinical Professor of Internal Medicine (Hematology/Oncology) · University of Michigan Rogel Cancer Center
Francis Worden is Nancy Wigginton Oncology Research Professor of Thyroid Cancer; Clinical Professor of Internal Medicine (Hematology/Oncology) at University of Michigan Rogel Cancer Center. OpenAlex indexes 549 publications with 22,578 citations (h-index 64); ClinicalTrials.gov lists 14 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Francis Worden, MD, is Nancy Wigginton Oncology Research Professor of Thyroid Cancer at University of Michigan Rogel Cancer Center (Michigan Medicine). The public record shows 549 publications with 22,578 citations (h-index 64), centered on Head and Neck Cancer Studies, Thyroid Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 14 registered clinical trials, industry payments reported by 12 companies.
- Most recent indexed publication: 2026 · Clinical cancer research
- Top research focus: Head and Neck Cancer Studies
- 14 registered trials on ClinicalTrials.gov
- Open Payments reporting from 12 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 7 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 204.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 14 registered studies on ClinicalTrials.gov. The most recent:
- Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
Sponsor: M.D. Anderson Cancer Center
- Pembrolizumab for the Treatment of Locally Advanced and/or Recurrent Orbital or Periocular Cutaneous Squamous Cell Carcinoma
Sponsor: University of Michigan Rogel Cancer Center
Industry payments
Updated 27 Aug 2026
12 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year202520 payments$19,546openpaymentsdata.cms.gov ↗
- Eisai Inc.Program year20254 payments
- Merck Sharp & Dohme LLCProgram year20253 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
29.7%Serotonin-3 Receptor Antagonist11.7%Ondansetron Odt70%Ondansetron Hcl30%Part D≥31 patientsCorticosteroid9.6%Prednisone100%Part D≥31 patientsHormonal (systemic)
26.5%l-Thyroxine26.5%Levothyroxine Sodium87%Synthroid13%Part D<11 patientsNervous system
17.3%Phenothiazine8.8%Prochlorperazine Maleate100%Part D≥39 patientsOpioid Agonist5.1%Oxycodone Hcl62%Morphine Sulfate Er38%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 27 Aug 2026
111 congress contributions (2004–2025) across AACE, AACR, ASCO, ASTRO, ENDO, ESMO per OpenAlex. The most recent:
- Abstract CT038: Phase 1 study of anti-CCR8 antibody CHS-114 with and without anti-PD-1 antibody toripalimab in patients with advanced solid tumors
AACR Annual Meeting
AACR2025Presenting author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- FDG-PET-Based Selective Deescalation of Chemoradiation in Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma: A Multicenter Phase II Trial.
Clinical cancer research
Clinical Trial2026 - Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers.
Clinical cancer research
Article2024 - Upfront Neck Dissection for Treatment Selection and Improvement in Quality of Life as a Novel Treatment Paradigm for Deintensification in HPV+ OPSCC.
Clinical cancer research
Clinical Trial2024 - A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Clinical cancer research
Clinical Trial2023
Most-cited works
by citation count (OpenAlex)- 01Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckArticle5,121 citations2016
- 02Integrative clinical genomics of metastatic cancerArticle937 citations2017
- 03
- 04Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid CancersArticle787 citations2020
- 05
Network
Updated 27 Aug 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/cv/francis-worden-md-1
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Francis-Worden
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
ascopost.com/videos/2020-multidisciplinary-head-and-neck-cancers-symposium/francis-worden-on-the-role-of-induction-chemotherapy-in-laryngeal-preservation
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Other
uofmhealth.org/news-release/asco-2025-rogel-recap
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uofmhealth.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uofmhealth.org ↗
Editorial & leadership roles
journal and society appointments- Panel Member
NCCN Clinical Practice Guidelines in Oncology, Head and Neck Cancers
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pubmed.ncbi.nlm.nih.gov ↗
Secondary affiliations
appointments beyond the home institution- Program Director
Hematology/Oncology Fellowship Program, University of Michigan
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uofmhealth.org ↗ - Affiliated physician
Veterans Affairs Ann Arbor Healthcare System
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Media & interviews
press, podcasts and appearances- Moderator
"Ask the Professors" panel discussion, International Thyroid Tumor Board webinar series (with Dr. Michael Tuttle and other panelists)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →tiro.expert ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Mark Shrime, MD
Harvard University
Neal Futran, MD, DMD
University of Washington
Everett Vokes, MD
University of Chicago
Maura Gillison, MD
The University of Texas MD Anderson Cancer Center